A Phase 1/2, Open-label, Multi-Center Study of Dually Armored Chimeric Antigen Receptor (CAR) T-cells (TmPSMA-02) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
An open-label, multi-center, Phase 1/2 study to determine the safety, tolerability, and feasibility of dosing adult patients with mCRPC with genetically modified autologous T-cells (TmPSMA-02) engineered to express a CAR capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T-cell.
100 Clinical Results associated with Tceleron Therapeutics, Inc.
0 Patents (Medical) associated with Tceleron Therapeutics, Inc.
100 Deals associated with Tceleron Therapeutics, Inc.
100 Translational Medicine associated with Tceleron Therapeutics, Inc.